6-APB: Difference between revisions
>Unity Grammatics |
>LockPicker m Revised german legal status |
||
Line 186: | Line 186: | ||
==Legal status== | ==Legal status== | ||
*'''Australia and New Zealand | *'''Australia and New Zealand''': Certain countries contain a "substantially similar" catch-all clause in their drug law, such as New Zealand and Australia. This includes 6-APB as it is similar in chemical structure to the class A drug MDA, meaning 6-APB may be viewed as a controlled substance analogue in these jurisdictions.{{citation needed}} | ||
*'''Canada | *'''Canada''': 6-APB is Schedule III in Canada as it is an analogue of MDA. The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.{{citation needed}} | ||
*'''Germany | *'''Germany''': 6-APB is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> as of September 1, 1984.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl113s2274.pdf%27%5D|title=Siebenundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 18, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> | ||
*'''Italy | *'''Italy''': 6-APB is illegal in Italy.<ref>http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf</ref> | ||
*'''Sweden | *'''Sweden''': 6-APB is prohibited in Sweden as a "health hazard" as of 2009.{{citation needed}} | ||
*'''United Kingdom | *'''United Kingdom''': On June 10, 2013, 6-APB and some analogues were classified as Temporary Class Drugs in the U.K. following an ACMD recommendation. On March 5, 2014, the U.K. Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.<ref>http://www.legislation.gov.uk/uksi/2014/1106/contents/made</ref> | ||
*'''United States | *'''United States''': 6-APB is unscheduled in the United States, but not currently approved by the Food and Drug Administration for human consumption.{{citation needed}} | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[ | *[[Research chemicals]] | ||
*[[Benzofuran]] | *[[Benzofuran]] | ||
*[[Entactogen]] | *[[Entactogen]] |